居里 2024年度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes¨Nox Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes¨NoxIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).xYes¨NoIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer¨Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared orissued its audit report.¨If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.xIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant (without admitting that any person whose sharesare not included in such calculation is an affiliate) based on the last reported sale price of the common stock on June 28, 2024 was approximately $40.6 million.As of March 27, 2025, there were 8,487,818 shares of the registrant’s common stock outstanding. DOCUMENTS INCORPORATED BY REFERENCESpecified portions of the registrant’s proxy statement for the annual meeting of stockholders scheduled to be held on May 20, 2025, which are to be filed with the Commission not later than 120 days after the close of the Registrant’s fiscal year ended December 31, 2024 pursuant to Regulation 14A, have beenincorporated by reference in Items 10-14 of Part III of this Annual Report on Form 10-K. CURIS, INC.TABLE OF CONTENTSForm 10-KPART I ITEM 1.BUSINESSITEM 1A.RISK FACTORSITEM 1B.UNRESOLVED STAFF COMMENTSITEM 1C.CYBERSECURITYITEM 2.PROPERTIESITEM 3.LEGAL PROCEEDINGSITEM 4.MINE SAFETY DISCLOSURES PART II PART I Cautionary Note Regarding Forward-Looking Statements and Industry DataThis Annual Report on Form 10-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. All statements other than statements of historical factcontained in this Annual Report are statements that could be deemed forward-looking statements, including without limitationany statements with respect to the plans, strategies and objectives of management for future operations; statements concerningproduct research, development and commercialization plans, timelines and anticipated results; statements of expectation orbelief; statements with respect to clinical trials and studies; statements with respect to royalties and milestones; statements withrespect to the therapeutic potential of drug candidates; expectations of revenue, expenses, earnings or losses from operations,or other financial results; and statements of assumptions underlying any of the foregoing. Without limiting the foregoing, thewords such as “expect(s)”, “believe(s)”, “will”, “may”, “anticipate(s)”, “focus(es)”, “plans”, “mission”, “strategy”,“potential”,“estimate(s)”, “opportunity”,“intend”, “project”, “seek”, “should”, “would”, “likelihood”, and similarexpressions, whether in the negative or affirmative, are intended to identify forward-looking statements, although not allforward-looking statements contain thes